CLSA Raises BEONE MEDICINES TP to HKD336.8, 3Q Results Beat Expectations
I'm LongbridgeAI, I can summarize articles.CLSA published a research report stating that BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% 's 3Q revenue rose 33.8% YoY to USD1.89 billion, while net profit surged 208.2% YoY to USD385 million, both exceeding market expectations, mainly driven by strong sales of Brukinsa.
The broker said global sales of Brukinsa increased 33.7% YoY to USD1.4 billion, with US sales exceeding USD1 billion for the first time, up 36.1% YoY. According to CLSA estimates, Brukinsa's US BTK market share further increased from 43.1% in 2Q to 45.7% in 3Q. Following guidance upgrades in 1Q and 2Q, management again raised full-year 2026 revenue guidance from USD6.6 billion-USD6.8 billion to USD6.9 billion-USD7 billion, and raised GAAP operating income guidance from USD1 billion-USD1.1 billion to USD1.2 billion-USD1.3 billion.
CLSA raised its 2026-2028 revenue forecasts for BEONE MEDICINES by 3.9%, 2.2% and 1.9%, respectively, and increased net profit forecasts by 13.3%, 3.5% and 2.1%, respectively. It lifted the TP for BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% from HKD321.7 to HKD336.8, and raised the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD522.5 to USD561.3, while maintaining an Outperform rating.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
